SCHEMBL1277331

SCHEMBL1277331

C/C(=C\c1ccc(Oc2ccc(O)cc2)cc1-c1ccc(O)cc1)C(=O)NC(=N)N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 5/20 0.38
PARP10 Q53GL7 1/20 0.36
HDAC3 O15379 2/20 0.35
HDAC1 Q13547 2/20 0.35
CHEK2 O96017 4/20 0.33
ESR1 P03372 3/20 0.33
NCOR2 Q9Y618 1/20 0.33
PELI1 Q96FA3 1/20 0.33
PKM P14618 1/20 0.32
ALDH1A1 P00352 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
THRA P10827 1/20 0.32
THRB P10828 1/20 0.32
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
ACACB O00763 1/20 0.31
ACACA Q13085 1/20 0.31
ESR2 Q92731 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1277409 0.92 ALDH1A1 (0.36) HDAC8CHEK2ALDH1A1
SCHEMBL1277638 0.91 HDAC8 (0.45) HDAC8HDAC3HDAC1ESR1NCOR2
SCHEMBL1277392 0.87 HSD17B1 (0.36) HDAC8ESR1PELI1ESR2MEN1
SCHEMBL1277438 0.85 SLC9A3 (0.40) PELI1ALDH1A1NPSR1MEN1KMT2A
SCHEMBL1277265 0.84 DHODH (0.39) ESR1PELI1ESR2
SCHEMBL1277249 0.83 F10 (0.36) PELI1
SCHEMBL1277449 0.82 CA1 (0.35) HDAC8CHEK2PELI1ALDH1A1THRA
SCHEMBL12709258 0.81 HSD17B1 (0.35) PELI1
SCHEMBL1277347 0.81 BACE1 (0.36)
SCHEMBL1277277 0.81 BACE1 (0.40) ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES SLC9A3, NHERF1, SLC9A2 HDAC8 730/4885PARP10 1709/4885HDAC3 165/4885
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES SLC9A3, NHERF1, SLC9A2 HDAC8 730/4885PARP10 1709/4885HDAC3 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.